JP7448310B2 - セルフリー核酸のフラグメントームプロファイリングのための方法 - Google Patents
セルフリー核酸のフラグメントームプロファイリングのための方法 Download PDFInfo
- Publication number
- JP7448310B2 JP7448310B2 JP2018568937A JP2018568937A JP7448310B2 JP 7448310 B2 JP7448310 B2 JP 7448310B2 JP 2018568937 A JP2018568937 A JP 2018568937A JP 2018568937 A JP2018568937 A JP 2018568937A JP 7448310 B2 JP7448310 B2 JP 7448310B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- cell
- multiparametric
- genome
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 310
- 150000007523 nucleic acids Chemical class 0.000 title description 18
- 102000039446 nucleic acids Human genes 0.000 title description 16
- 108020004707 nucleic acids Proteins 0.000 title description 16
- 108020004414 DNA Proteins 0.000 claims description 656
- 102000053602 DNA Human genes 0.000 claims description 654
- 239000012634 fragment Substances 0.000 claims description 628
- 206010028980 Neoplasm Diseases 0.000 claims description 284
- 108010047956 Nucleosomes Proteins 0.000 claims description 216
- 210000001623 nucleosome Anatomy 0.000 claims description 139
- 238000004458 analytical method Methods 0.000 claims description 132
- 201000011510 cancer Diseases 0.000 claims description 113
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 77
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 201000010099 disease Diseases 0.000 claims description 73
- 238000005259 measurement Methods 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 48
- 238000001514 detection method Methods 0.000 claims description 44
- 238000012163 sequencing technique Methods 0.000 claims description 37
- 230000006870 function Effects 0.000 claims description 32
- 238000000638 solvent extraction Methods 0.000 claims description 21
- 238000007619 statistical method Methods 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000012165 high-throughput sequencing Methods 0.000 claims description 4
- 206010061309 Neoplasm progression Diseases 0.000 claims description 2
- 230000008482 dysregulation Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000005751 tumor progression Effects 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims 1
- 238000009826 distribution Methods 0.000 description 276
- 230000002068 genetic effect Effects 0.000 description 157
- 239000000523 sample Substances 0.000 description 132
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 109
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 108
- 230000005856 abnormality Effects 0.000 description 98
- 238000012360 testing method Methods 0.000 description 97
- 230000014509 gene expression Effects 0.000 description 83
- 108091028043 Nucleic acid sequence Proteins 0.000 description 76
- 210000002381 plasma Anatomy 0.000 description 65
- 238000012549 training Methods 0.000 description 61
- 230000002159 abnormal effect Effects 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 50
- 239000012472 biological sample Substances 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 44
- 108010077544 Chromatin Proteins 0.000 description 43
- 210000003483 chromatin Anatomy 0.000 description 43
- 238000013507 mapping Methods 0.000 description 43
- 230000000869 mutational effect Effects 0.000 description 42
- 238000003556 assay Methods 0.000 description 34
- 238000004422 calculation algorithm Methods 0.000 description 34
- 230000000875 corresponding effect Effects 0.000 description 34
- 230000003211 malignant effect Effects 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 206010069754 Acquired gene mutation Diseases 0.000 description 32
- 230000000392 somatic effect Effects 0.000 description 32
- 230000037439 somatic mutation Effects 0.000 description 32
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 31
- 201000005202 lung cancer Diseases 0.000 description 31
- 208000020816 lung neoplasm Diseases 0.000 description 31
- 101150029707 ERBB2 gene Proteins 0.000 description 24
- 230000001594 aberrant effect Effects 0.000 description 24
- 230000004075 alteration Effects 0.000 description 23
- 230000003321 amplification Effects 0.000 description 20
- 230000015654 memory Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 238000013467 fragmentation Methods 0.000 description 19
- 238000006062 fragmentation reaction Methods 0.000 description 19
- 241000894007 species Species 0.000 description 19
- 238000003860 storage Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 238000010801 machine learning Methods 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 238000011528 liquid biopsy Methods 0.000 description 17
- 230000011987 methylation Effects 0.000 description 17
- 238000007069 methylation reaction Methods 0.000 description 17
- 108010085793 Neurofibromin 1 Proteins 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 208000026310 Breast neoplasm Diseases 0.000 description 15
- 102000001301 EGF receptor Human genes 0.000 description 15
- 108010033040 Histones Proteins 0.000 description 15
- 108700009124 Transcription Initiation Site Proteins 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 108060006698 EGF receptor Proteins 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 14
- 102000007530 Neurofibromin 1 Human genes 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 210000004602 germ cell Anatomy 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 14
- 230000030833 cell death Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000037437 driver mutation Effects 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 10
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 10
- 230000001640 apoptogenic effect Effects 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 238000005315 distribution function Methods 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000001338 necrotic effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 8
- 102000006947 Histones Human genes 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000008520 organization Effects 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 239000003086 colorant Substances 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 230000002055 immunohistochemical effect Effects 0.000 description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 230000008707 rearrangement Effects 0.000 description 7
- 239000000439 tumor marker Substances 0.000 description 7
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000007403 mPCR Methods 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 5
- 102000036365 BRCA1 Human genes 0.000 description 5
- 108700020463 BRCA1 Proteins 0.000 description 5
- 101150072950 BRCA1 gene Proteins 0.000 description 5
- 102100030708 GTPase KRas Human genes 0.000 description 5
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 5
- 101150001753 MPL gene Proteins 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 108700040618 BRCA1 Genes Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000013145 classification model Methods 0.000 description 4
- 230000010405 clearance mechanism Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 238000003909 pattern recognition Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102200048928 rs121434568 Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 101150039808 Egfr gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 101150105104 Kras gene Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 230000002547 anomalous effect Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000033077 cellular process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000007418 data mining Methods 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000010339 medical test Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- 238000012070 whole genome sequencing analysis Methods 0.000 description 3
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 108091036060 Linker DNA Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- -1 cfDNA Chemical class 0.000 description 2
- 101150044072 cn gene Proteins 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008995 epigenetic change Effects 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005861 gene abnormality Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 201000003733 ovarian melanoma Diseases 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102200048955 rs121434569 Human genes 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010065163 Clonal evolution Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100022882 Deoxyribonuclease-2-alpha Human genes 0.000 description 1
- 101710167375 Deoxyribonuclease-2-alpha Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 102000018754 Histone Chaperones Human genes 0.000 description 1
- 108010052497 Histone Chaperones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101150083321 Nf1 gene Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102000013380 Smoothened Receptor Human genes 0.000 description 1
- 101710090597 Smoothened homolog Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003709 image segmentation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000012628 principal component regression Methods 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 102200048929 rs121913444 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021174556A JP2022025101A (ja) | 2016-07-06 | 2021-10-26 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
| JP2024091417A JP2024119898A (ja) | 2016-07-06 | 2024-06-05 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359151P | 2016-07-06 | 2016-07-06 | |
| US62/359,151 | 2016-07-06 | ||
| US201662420167P | 2016-11-10 | 2016-11-10 | |
| US62/420,167 | 2016-11-10 | ||
| US201662437172P | 2016-12-21 | 2016-12-21 | |
| US62/437,172 | 2016-12-21 | ||
| US201762489399P | 2017-04-24 | 2017-04-24 | |
| US62/489,399 | 2017-04-24 | ||
| PCT/US2017/040986 WO2018009723A1 (en) | 2016-07-06 | 2017-07-06 | Methods for fragmentome profiling of cell-free nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021174556A Division JP2022025101A (ja) | 2016-07-06 | 2021-10-26 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531700A JP2019531700A (ja) | 2019-11-07 |
| JP2019531700A5 JP2019531700A5 (enExample) | 2020-08-13 |
| JP7448310B2 true JP7448310B2 (ja) | 2024-03-12 |
Family
ID=60913158
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568937A Active JP7448310B2 (ja) | 2016-07-06 | 2017-07-06 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
| JP2021174556A Withdrawn JP2022025101A (ja) | 2016-07-06 | 2021-10-26 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
| JP2024091417A Pending JP2024119898A (ja) | 2016-07-06 | 2024-06-05 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021174556A Withdrawn JP2022025101A (ja) | 2016-07-06 | 2021-10-26 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
| JP2024091417A Pending JP2024119898A (ja) | 2016-07-06 | 2024-06-05 | セルフリー核酸のフラグメントームプロファイリングのための方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP3481966B1 (enExample) |
| JP (3) | JP7448310B2 (enExample) |
| KR (1) | KR102610098B1 (enExample) |
| CN (1) | CN109689891B (enExample) |
| AU (1) | AU2017292854B2 (enExample) |
| BR (1) | BR112019000296A2 (enExample) |
| CA (1) | CA3030038A1 (enExample) |
| ES (1) | ES2967443T3 (enExample) |
| MX (1) | MX2019000037A (enExample) |
| SG (1) | SG11201811556RA (enExample) |
| WO (1) | WO2018009723A1 (enExample) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US8825412B2 (en) | 2010-05-18 | 2014-09-02 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| EP2656263B1 (en) | 2010-12-22 | 2019-11-06 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| JP6153874B2 (ja) | 2011-02-09 | 2017-06-28 | ナテラ， インコーポレイテッド | 非侵襲的出生前倍数性呼び出しのための方法 |
| AU2012242847B2 (en) | 2011-04-15 | 2017-01-19 | The Johns Hopkins University | Safe sequencing system |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| ES2701742T3 (es) | 2012-10-29 | 2019-02-25 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| CN113774132A (zh) | 2014-04-21 | 2021-12-10 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| DK3294906T3 (en) | 2015-05-11 | 2024-08-05 | Natera Inc | Methods for determining ploidy |
| US10453556B2 (en) | 2015-07-23 | 2019-10-22 | The Chinese University Of Hong Kong | Analysis of fragmentation patterns of cell-free DNA |
| WO2017027653A1 (en) | 2015-08-11 | 2017-02-16 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| EP3433382B1 (en) | 2016-03-25 | 2021-09-01 | Karius, Inc. | Synthetic nucleic acid spike-ins |
| DK3443119T3 (da) | 2016-04-15 | 2022-05-23 | Natera Inc | Fremgangsmåde til bestemmelse af lunge cancer |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| WO2018119452A2 (en) | 2016-12-22 | 2018-06-28 | Guardant Health, Inc. | Methods and systems for analyzing nucleic acid molecules |
| ES2990117T3 (es) | 2017-01-25 | 2024-11-28 | Univ Hong Kong Chinese | Aplicaciones de diagnóstico que utilizan fragmentos de ácido nucleico |
| WO2019016353A1 (en) * | 2017-07-21 | 2019-01-24 | F. Hoffmann-La Roche Ag | CLASSIFICATION OF SOMATIC MUTATIONS FROM A HETEROGENEOUS SAMPLE |
| CN120400338A (zh) | 2017-08-07 | 2025-08-01 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| WO2019060716A1 (en) | 2017-09-25 | 2019-03-28 | Freenome Holdings, Inc. | SAMPLE EXTRACTION METHODS AND SYSTEMS |
| WO2019118926A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| EP3743518A4 (en) * | 2018-01-24 | 2021-09-29 | Freenome Holdings, Inc. | METHODS AND SYSTEMS FOR DETECTING ANOMALY IN PATTERNS OF NUCLEIC ACIDS |
| IL321982A (en) * | 2018-02-27 | 2025-09-01 | Univ Cornell | Systems and methods for detecting residual disease |
| JP2021519607A (ja) | 2018-02-27 | 2021-08-12 | コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | ゲノムワイド統合による循環腫瘍ｄｎａの超音波感受性検出 |
| WO2019173552A1 (en) | 2018-03-08 | 2019-09-12 | St. John's University | Circulating serum cell-free dna biomarkers and methods |
| WO2019178289A1 (en) | 2018-03-13 | 2019-09-19 | Grail, Inc. | Method and system for selecting, managing, and analyzing data of high dimensionality |
| WO2019178563A1 (en) * | 2018-03-15 | 2019-09-19 | The Board Of Trustees Of Leland Stanford Junior University | Methods using nucleic acid signals for revealing biological attributes |
| WO2019200404A2 (en) * | 2018-04-13 | 2019-10-17 | Grail, Inc. | Multi-assay prediction model for cancer detection |
| CA3095056A1 (en) * | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
| DK3781714T3 (da) | 2018-04-14 | 2026-03-30 | Natera Inc | Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna |
| CN112888459B (zh) | 2018-06-01 | 2023-05-23 | 格里尔公司 | 卷积神经网络系统及数据分类方法 |
| WO2020006369A1 (en) * | 2018-06-29 | 2020-01-02 | Guardant Health, Inc. | Methods and systems for analysis of ctcf binding regions in cell-free dna |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| JP7637615B2 (ja) * | 2018-09-04 | 2025-02-28 | ガーダント ヘルス， インコーポレイテッド | 無細胞核酸試料におけるアレル不均衡を検出するための方法およびシステム |
| EP3815005A4 (en) * | 2018-10-08 | 2022-03-30 | Freenome Holdings, Inc. | Transcription factor profiling |
| GB201818159D0 (en) * | 2018-11-07 | 2018-12-19 | Cancer Research Tech Ltd | Enhanced detection of target dna by fragment size analysis |
| EP4428234B1 (en) | 2018-11-21 | 2025-12-24 | Karius, Inc. | Direct-to-library methods, systems, and compositions |
| WO2020106987A1 (en) * | 2018-11-21 | 2020-05-28 | Karius, Inc. | Detection and prediction of infectious disease |
| US10468141B1 (en) * | 2018-11-28 | 2019-11-05 | Asia Genomics Pte. Ltd. | Ancestry-specific genetic risk scores |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| TW202536188A (zh) * | 2018-12-19 | 2025-09-16 | 香港中文大學 | 游離dna末端特徵 |
| WO2020127629A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Identification of global sequence features in whole genome sequence data from circulating nucelic acid |
| WO2020132499A2 (en) * | 2018-12-21 | 2020-06-25 | Grail, Inc. | Systems and methods for using fragment lengths as a predictor of cancer |
| WO2020150258A1 (en) * | 2019-01-15 | 2020-07-23 | Luminist, Inc. | Methods and systems for detecting liver disease |
| KR102916051B1 (ko) * | 2019-01-24 | 2026-01-21 | 일루미나, 인코포레이티드 | 장기 건강 및 질환을 모니터링하기 위한 방법 및 시스템 |
| CA3126428A1 (en) | 2019-01-31 | 2020-08-06 | Guardant Health, Inc. | Compositions and methods for isolating cell-free dna |
| CA3130203A1 (en) | 2019-02-12 | 2020-08-20 | Tempus Labs, Inc. | Detection of human leukocyte antigen loss of heterozygosity |
| US11475978B2 (en) | 2019-02-12 | 2022-10-18 | Tempus Labs, Inc. | Detection of human leukocyte antigen loss of heterozygosity |
| WO2020176659A1 (en) * | 2019-02-27 | 2020-09-03 | Guardant Health, Inc. | Methods and systems for determining the cellular origin of cell-free dna |
| US20220154249A1 (en) * | 2019-04-15 | 2022-05-19 | Natera, Inc. | Improved liquid biopsy using size selection |
| US12497662B2 (en) | 2019-04-16 | 2025-12-16 | Grail, Inc. | Systems and methods for tumor fraction estimation from small variants |
| US11869661B2 (en) | 2019-05-22 | 2024-01-09 | Grail, Llc | Systems and methods for determining whether a subject has a cancer condition using transfer learning |
| US11939636B2 (en) | 2019-05-31 | 2024-03-26 | Guardant Health, Inc. | Methods and systems for improving patient monitoring after surgery |
| EP3980559A1 (en) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| EP3997242B1 (en) * | 2019-07-09 | 2026-04-08 | The Translational Genomics Research Institute | Methods of detecting disease and treatment response in cfdna |
| US20220301654A1 (en) * | 2019-08-28 | 2022-09-22 | Grail, Llc | Systems and methods for predicting and monitoring treatment response from cell-free nucleic acids |
| CN110706749B (zh) * | 2019-09-10 | 2022-06-10 | 至本医疗科技（上海）有限公司 | 一种基于组织器官分化层次关系的癌症类型预测系统和方法 |
| CA3151538A1 (en) | 2019-09-30 | 2021-04-08 | Stefanie Ann Ward Mortimer | Compositions and methods for analyzing cell-free dna in methylation partitioning assays |
| EP4715839A2 (en) | 2019-10-11 | 2026-03-25 | Guardant Health, Inc. | Use of cell free bacterial nucleic acids for detection of cancer |
| CN114746560A (zh) | 2019-11-26 | 2022-07-12 | 夸登特健康公司 | 改进甲基化多核苷酸结合的方法、组合物和系统 |
| KR102586651B1 (ko) * | 2019-11-29 | 2023-10-11 | 주식회사 지씨지놈 | 인공지능 기반 염색체 이상 검출 방법 |
| CN115151657A (zh) * | 2019-12-20 | 2022-10-04 | 安可济控股有限公司 | 用于疾病检测的方法和系统 |
| WO2021130356A1 (en) * | 2019-12-24 | 2021-07-01 | Vib Vzw | Disease detection in liquid biopsies |
| IL295297A (en) | 2020-02-14 | 2022-10-01 | Univ Johns Hopkins | Methods and materials for assessing nucleic acids |
| AU2021227920A1 (en) * | 2020-02-28 | 2022-09-08 | Grail, Llc | Systems and methods for calling variants using methylation sequencing data |
| CA3177127A1 (en) | 2020-04-30 | 2021-11-04 | Guardant Health, Inc. | Methods for sequence determination using partitioned nucleic acids |
| IL298458A (en) * | 2020-05-22 | 2023-01-01 | Aqtual Inc | Methods for characterizing cell-free nucleic acid fragments |
| EP4179111B1 (en) | 2020-07-10 | 2024-04-03 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| WO2022026761A1 (en) | 2020-07-30 | 2022-02-03 | Guardant Health, Inc. | Methods for isolating cell-free dna |
| CN116157868A (zh) * | 2020-08-18 | 2023-05-23 | 德尔菲诊断公司 | 用于游离dna片段大小密度以评估癌症的方法和系统 |
| WO2022046947A1 (en) | 2020-08-25 | 2022-03-03 | Guardant Health, Inc. | Methods and systems for predicting an origin of a variant |
| EP4214329A4 (en) * | 2020-09-17 | 2024-12-04 | The Regents of the University of Colorado, a body corporate | Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisions |
| WO2022073012A1 (en) | 2020-09-30 | 2022-04-07 | Guardant Health, Inc. | Compositions and methods for analyzing dna using partitioning and a methylation-dependent nuclease |
| WO2022087309A1 (en) | 2020-10-23 | 2022-04-28 | Guardant Health, Inc. | Compositions and methods for analyzing dna using partitioning and base conversion |
| CA3199829A1 (en) | 2020-11-30 | 2022-06-02 | Guardant Health, Inc. | Compositions and methods for enriching methylated polynucleotides |
| CN114634982A (zh) * | 2020-12-15 | 2022-06-17 | 广州市基准医疗有限责任公司 | 一种检测多核苷酸变异的方法 |
| EP4015650A1 (en) * | 2020-12-18 | 2022-06-22 | Nipd Genetics Biotech Limited | Methods for classifying a sample into clinically relevant categories |
| WO2022140629A1 (en) | 2020-12-23 | 2022-06-30 | Guardant Health, Inc. | Methods and systems for analyzing methylated polynucleotides |
| EP4729633A2 (en) | 2021-02-12 | 2026-04-22 | Guardant Health, Inc. | Methods for detecting nucleic acid variants |
| EP4314329A1 (en) | 2021-03-25 | 2024-02-07 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
| EP4320277A4 (en) * | 2021-04-08 | 2025-03-05 | Delfi Diagnostics, Inc. | CANCER DETECTION METHOD USING GENOME-WIDE CELL-FREE DNA FRAGMENTATION PROFILES |
| WO2022248844A1 (en) * | 2021-05-24 | 2022-12-01 | University Of Essex Enterprises Limited | Method and system for identifying genomic regions with condition sensitive occupancy/positioning of nucleosomes and/or chromatin |
| KR102927037B1 (ko) * | 2021-05-28 | 2026-02-13 | 주식회사 지씨지놈 | 조직 특이적 조절 지역의 무세포 dna 분포를 이용한 인공지능 기반 암 조기진단 방법 |
| CN113838533B (zh) * | 2021-08-17 | 2024-03-12 | 福建和瑞基因科技有限公司 | 一种癌症检测模型及其构建方法和试剂盒 |
| EP4433611A4 (en) * | 2021-11-17 | 2025-10-08 | Univ Leland Stanford Junior | SYSTEMS AND METHODS FOR GENE EXPRESSION AND TISSUE OF ORIGIN INFERENCE FROM CIRCULATING FREE DNA |
| KR102884871B1 (ko) * | 2022-01-26 | 2025-11-11 | 권창혁 | 암 판별 장치 및 암 판별 방법 |
| CA3245713A1 (en) * | 2022-03-17 | 2023-09-21 | Delfi Diagnostics, Inc. | CANCER SURVEILLANCE METHOD USING FRAGMENTATION PROFILES |
| EP4504971A1 (en) | 2022-04-07 | 2025-02-12 | Guardant Health, Inc. | Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules |
| EP4532762A1 (en) * | 2022-06-02 | 2025-04-09 | The Board Of Trustees Of The Leland Stanford Junior University | Single molecule sequencing and methylation profiling of cell-free dna |
| EP4547857A1 (en) | 2022-06-30 | 2025-05-07 | Guardant Health, Inc. | Enrichment of aberrantly methylated dna |
| US20240043935A1 (en) * | 2022-07-29 | 2024-02-08 | Centre For Novostics Limited | Epigenetics analysis of cell-free dna |
| WO2024073508A2 (en) | 2022-09-27 | 2024-04-04 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
| CN115295074B (zh) * | 2022-10-08 | 2022-12-16 | 南京世和基因生物技术股份有限公司 | 基因标志物在恶性肺结节筛查中的应用、筛查模型的构建方法和检测装置 |
| WO2024112643A1 (en) * | 2022-11-21 | 2024-05-30 | Foundation Medicine, Inc. | Fragmentomics based identification of tumor-specific copy number alteration states in liquid biopsy |
| WO2024138180A2 (en) | 2022-12-22 | 2024-06-27 | Guardant Health, Inc. | Integrated targeted and whole genome somatic and dna methylation sequencing workflows |
| EP4638781A2 (en) | 2022-12-22 | 2025-10-29 | Guardant Health, Inc. | Methods involving methylation preserving amplification with error correction |
| EP4705522A1 (en) | 2023-05-05 | 2026-03-11 | Guardant Health, Inc. | Cell-free dna blood-based test for cancer screening |
| CN116665784B (zh) * | 2023-05-31 | 2025-12-30 | 华中农业大学 | 基于cfDNA全基因组测序数据识别染色质开放区域的方法、癌症预测模型及系统 |
| WO2025019370A1 (en) * | 2023-07-14 | 2025-01-23 | Natera, Inc. | Methods for assaying circulating tumor dna |
| WO2025029475A1 (en) | 2023-07-28 | 2025-02-06 | Guardant Health, Inc. | Methods to enrich nucleotide variants by negative selection |
| WO2025038399A1 (en) | 2023-08-11 | 2025-02-20 | Guardant Health, Inc. | Methylated enrichment methods for single-molecule genetic and epigenetic sequencing |
| CN117230165A (zh) * | 2023-09-01 | 2023-12-15 | 深圳湾实验室 | 一种无创产前检测胎儿染色体拷贝数异常的优化方法 |
| WO2025064706A1 (en) | 2023-09-19 | 2025-03-27 | Guardant Health, Inc. | Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules |
| WO2025076452A1 (en) | 2023-10-06 | 2025-04-10 | Guardant Health, Inc. | Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules |
| WO2025207817A1 (en) | 2024-03-26 | 2025-10-02 | Guardant Health, Inc. | Method of determining the likelihood of a disease by combining biomarkers and imaging |
| WO2025208044A1 (en) | 2024-03-28 | 2025-10-02 | Guardant Health, Inc. | Methods for cancer detection using molecular patterns |
| WO2025205006A1 (ja) * | 2024-03-29 | 2025-10-02 | ソニーグループ株式会社 | 分析方法、クロマチン状態を分類する方法、がん検査方法、分析システム、がん又は微小残存病変の検査システムおよび分析キット |
| WO2025235889A1 (en) | 2024-05-10 | 2025-11-13 | Guardant Health, Inc. | Methods involving multiplexed pooled pcr |
| WO2025250544A1 (en) | 2024-05-31 | 2025-12-04 | Guardant Health, Inc. | Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna |
| WO2026043718A1 (en) | 2024-08-21 | 2026-02-26 | Guardant Health, Inc. | Methods to monitor patients treated with a cancer vaccine |
| WO2026073140A1 (en) | 2024-09-27 | 2026-04-02 | Guardant Health, Inc. | Framework to identify genomic regions indicative of one or more biological conditions |
| WO2026076332A1 (en) | 2024-10-03 | 2026-04-09 | Guardant Health, Inc. | Methods involving multi-modal tumor variant identification and tracking of tumor molecules |
| WO2026090570A1 (en) | 2024-10-24 | 2026-04-30 | Guardant Health, Inc. | Detecting the presence of a biological condition based on a nucleic acid sample data analysis |
| CN119905148B (zh) * | 2024-12-30 | 2026-02-06 | 西藏自治区农牧科学院水产科学研究所 | 一种核间等位基因表达分析方法、装置及存储介质 |
| CN120334449B (zh) * | 2025-06-20 | 2025-09-05 | 陕西右任故里茯砖茶股份有限公司 | 基于液相色谱的茯砖茶中金花菌发酵检测方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010049538A1 (en) | 2008-10-30 | 2010-05-06 | Centre de Recherche Public de la Santé | Biomarkers |
| WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2013121224A1 (en) | 2012-02-16 | 2013-08-22 | Oxford Nanopore Technologies Limited | Analysis of measurements of a polymer |
| WO2013192562A1 (en) | 2012-06-22 | 2013-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2016015058A2 (en) | 2014-07-25 | 2016-01-28 | University Of Washington | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101901345B (zh) * | 2009-05-27 | 2013-02-27 | 复旦大学 | 一种差异蛋白质组学的分类方法 |
| US11322224B2 (en) * | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2426217A1 (en) * | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
| CA2840418C (en) * | 2011-07-26 | 2019-10-29 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
| US9367663B2 (en) * | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| AU2013232123B2 (en) * | 2012-03-13 | 2014-10-30 | The Chinese University Of Hong Kong | Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis |
| CN108485940B (zh) * | 2012-04-12 | 2022-01-28 | 维里纳塔健康公司 | 拷贝数变异的检测和分类 |
| DE202013012824U1 (de) * | 2012-09-04 | 2020-03-10 | Guardant Health, Inc. | Systeme zum Erfassen von seltenen Mutationen und einer Kopienzahlvariation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20130309666A1 (en) * | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CN114574581A (zh) * | 2013-03-15 | 2022-06-03 | 夸登特健康公司 | 检测稀有突变和拷贝数变异的系统和方法 |
| EP3011052B1 (en) * | 2013-06-17 | 2019-05-22 | Verinata Health, Inc | Method for determining copy number variations in sex chromosomes |
| US9499870B2 (en) * | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| JP6659672B2 (ja) * | 2014-05-30 | 2020-03-04 | ベリナタ ヘルス インコーポレイテッド | 胎児染色体部分異数性およびコピー数変動の検出 |
| AU2015360298B2 (en) * | 2014-12-12 | 2018-06-07 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
-
2017
- 2017-07-06 CA CA3030038A patent/CA3030038A1/en active Pending
- 2017-07-06 AU AU2017292854A patent/AU2017292854B2/en active Active
- 2017-07-06 JP JP2018568937A patent/JP7448310B2/ja active Active
- 2017-07-06 SG SG11201811556RA patent/SG11201811556RA/en unknown
- 2017-07-06 EP EP17824931.4A patent/EP3481966B1/en active Active
- 2017-07-06 BR BR112019000296-0A patent/BR112019000296A2/pt not_active Application Discontinuation
- 2017-07-06 ES ES17824931T patent/ES2967443T3/es active Active
- 2017-07-06 EP EP23202039.6A patent/EP4322168A3/en active Pending
- 2017-07-06 MX MX2019000037A patent/MX2019000037A/es unknown
- 2017-07-06 CN CN201780054825.3A patent/CN109689891B/zh active Active
- 2017-07-06 WO PCT/US2017/040986 patent/WO2018009723A1/en not_active Ceased
- 2017-07-06 KR KR1020197003420A patent/KR102610098B1/ko active Active
-
2021
- 2021-10-26 JP JP2021174556A patent/JP2022025101A/ja not_active Withdrawn
-
2024
- 2024-06-05 JP JP2024091417A patent/JP2024119898A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010049538A1 (en) | 2008-10-30 | 2010-05-06 | Centre de Recherche Public de la Santé | Biomarkers |
| WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2013121224A1 (en) | 2012-02-16 | 2013-08-22 | Oxford Nanopore Technologies Limited | Analysis of measurements of a polymer |
| WO2013192562A1 (en) | 2012-06-22 | 2013-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2016015058A2 (en) | 2014-07-25 | 2016-01-28 | University Of Washington | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201811556RA (en) | 2019-01-30 |
| EP3481966B1 (en) | 2023-11-08 |
| KR20190026837A (ko) | 2019-03-13 |
| JP2024119898A (ja) | 2024-09-03 |
| CN109689891B (zh) | 2024-06-18 |
| KR102610098B1 (ko) | 2023-12-04 |
| WO2018009723A1 (en) | 2018-01-11 |
| EP3481966A4 (en) | 2019-08-07 |
| EP4322168A3 (en) | 2024-05-15 |
| JP2019531700A (ja) | 2019-11-07 |
| AU2017292854B2 (en) | 2023-08-17 |
| CA3030038A1 (en) | 2018-01-11 |
| EP3481966A1 (en) | 2019-05-15 |
| ES2967443T3 (es) | 2024-04-30 |
| MX2019000037A (es) | 2019-07-10 |
| CN109689891A (zh) | 2019-04-26 |
| AU2017292854A1 (en) | 2019-01-24 |
| EP4322168A2 (en) | 2024-02-14 |
| JP2022025101A (ja) | 2022-02-09 |
| BR112019000296A2 (pt) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102610098B1 (ko) | 무세포 핵산의 프래그멘톰 프로파일링을 위한 방법 | |
| US20190287645A1 (en) | Methods for fragmentome profiling of cell-free nucleic acids | |
| US12590326B2 (en) | Methods for fragmentome profiling of cell-free nucleic acids | |
| JP7689557B2 (ja) | 相同組換え欠損を推定するための統合された機械学習フレームワーク | |
| Braxton et al. | 3D genomic mapping reveals multifocality of human pancreatic precancers | |
| US11978535B2 (en) | Methods of detecting somatic and germline variants in impure tumors | |
| CN113228190B (zh) | 分类和/或鉴定癌症亚型的系统和方法 | |
| JP2026065085A (ja) | がんの進化の検出および診断 | |
| EP4107732A1 (en) | Methods and systems for a liquid biopsy assay | |
| US20250014679A1 (en) | Methods and Systems for Use in Cancer Prediction | |
| US20220301654A1 (en) | Systems and methods for predicting and monitoring treatment response from cell-free nucleic acids | |
| HK40008790B (en) | Methods for fragmentome profiling of cell-free nucleic acids | |
| HK40008790A (en) | Methods for fragmentome profiling of cell-free nucleic acids | |
| US20250137063A1 (en) | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing | |
| WO2025113619A1 (en) | Enrichment of clinically-relevant nucleic acids | |
| Bhogal | Detection and Characterization of Cancer Using cfDNA Fragmentomic Analysis | |
| Luo | Accurate and Integrative Detection of Copy Number Variants With High-Throughput Data | |
| Lin et al. | Combining mutation detection with fragmentomics features leads to improved tumor-informed ctDNA detection | |
| Scandino | Non-Invasive cancer detection: computational applications in liquid biopsy and radiomics | |
| JP2024535914A (ja) | 癌予後診断の方法 | |
| Zhao | Semi-Parametric Mixture Gaussian Model to Detect Breast Cancer Intra-Tumor Heterogeneity | |
| Parker et al. | Effects of germline and somatic events in candidate | |
| HK1205533A1 (en) | Mutational analysis of plasma dna for cancer detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200701 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200701 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210726 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211026 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220610 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220610 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220617 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220620 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220805 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240229 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7448310 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |